Epidermal Growth Factor Receptor, Somatostatin and Bcl-2 in Human Pancreatic Tumor Xenografts. An Immunohistochemical Study

Overview

Journal Pathol Oncol Res

Specialty Oncology

Date 1999 Jul 7

PMID 10393368

Citations 2

Authors

A Zalatnai

Affiliations

Soon will be listed here.

Abstract

Xenografted human pancreatic tumors (5 ductal adenocarcinomas, 1 leiomyosarcoma, altogether 26 samples) were investigated about their immunohistochemical expression of epidermal growth factor receptor (EGFR), somatostatin (SS) and bcl-2 protein. The expression of the EGFR varied from tumor to tumor. One originally negative carcinoma became immunoreactive during passagings, one tumor has lost its early positive expression, and in 3 cancer lines a phenotypically constant pattern was seen. SS immunoreactivity was practically absent in all tumor samples. Concerning bcl-2 expression, different staining patterns were observed among the carcinomas, but the leiomyosarcoma has retained its strong positivity during xenograftings. In the PZX-5 carcinoma line that was originally negative, the one month Sandostatin treatment induced the strong expression of bcl-2 protein suggesting a development of an acquired resistance against programmed cell death in this tumor.

Citing Articles

P-glycoprotein expression is induced in human pancreatic cancer xenografts during treatment with a cell cycle regulator, mimosine.

Zalatnai A Pathol Oncol Res. 2005; 11(3):164-9.

PMID: 16195770 DOI: 10.1007/BF02893393.

Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma.

Heinmoller E, Dietmaier W, Zirngibl H, Heinmoller P, Scaringe W, Jauch K Am J Pathol. 2000; 157(1):83-92.

PMID: 10880379 PMC: 1850206. DOI: 10.1016/S0002-9440(10)64520-8.

References

Fisher W, Doran T, Muscarella 2nd P, Boros L, Ellison E, Schirmer W . Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer. J Natl Cancer Inst. 1998; 90(4):322-4. DOI: 10.1093/jnci/90.4.322. View

Ohshio G, Suwa H, Imamura T, Yamaki K, Tanaka T, Hashimoto Y . An immunohistochemical study of bcl-2 and p53 protein expression in pancreatic carcinomas. Scand J Gastroenterol. 1998; 33(5):535-9. DOI: 10.1080/00365529850172124. View

Vidal C, Rauly I, Zeggari M, Delesque N, Esteve J, Saint-Laurent N . Up-regulation of somatostatin receptors by epidermal growth factor and gastrin in pancreatic cancer cells. Mol Pharmacol. 1994; 46(1):97-104. View

Hockenbery D, Zutter M, Hickey W, Nahm M, Korsmeyer S . BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci U S A. 1991; 88(16):6961-5. PMC: 52213. DOI: 10.1073/pnas.88.16.6961. View

Szende B, Zalatnai A, Schally A . Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci U S A. 1989; 86(5):1643-7. PMC: 286755. DOI: 10.1073/pnas.86.5.1643. View

Gower Jr W, Risch R, Godellas C, Fabri P . HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line. In Vitro Cell Dev Biol Anim. 2015; 30A(3):151-61. DOI: 10.1007/BF02631438. View

Nakanishi H, Ohsawa M, Naka N, Uchida A, Ochi T, Aozasa K . Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis. Oncology. 1997; 54(3):238-44. DOI: 10.1159/000227695. View

Wada M, Hosotani R, Lee J, Doi R, Koshiba T, Fujimoto K . An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells. Anticancer Res. 1998; 18(4A):2559-66. View

Wada M, Doi R, Hosotani R, Lee J, Fujimoto K, Koshiba T . Expression of Bcl-2 and PCNA in duct cells after pancreatic duct ligation in rats. Pancreas. 1997; 15(2):176-82. DOI: 10.1097/00006676-199708000-00010. View

10.

Saegusa M, Okayasu I . Bcl-2 is closely correlated with favorable prognostic factors and inversely associated with p53 protein accumulation in endometrial carcinomas: immunohistochemical and polymerase chain reaction/loss of heterozygosity findings. J Cancer Res Clin Oncol. 1997; 123(8):429-34. DOI: 10.1007/BF01372546. View

11.

Berchem G, Bosseler M, Sugars L, Voeller H, Zeitlin S, Gelmann E . Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res. 1995; 55(4):735-8. View

12.

Wang D, Johnston C, Buchanan K . Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications for pathogenesis. Cancer. 1997; 80(4):668-75. View

13.

Sinicrope F, Evans D, Leach S, Cleary K, Fenoglio C, Lee J . bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res. 1996; 2(12):2015-22. View

14.

Zalatnai A, Schally A . Treatment of N-nitrosobis(2-oxopropyl)amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analogue RC-160 microcapsules. Cancer Res. 1989; 49(7):1810-5. View

15.

Poston G, Townsend Jr C, Rajaraman S, Thompson J, Singh P . Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice. Pancreas. 1990; 5(2):151-7. DOI: 10.1097/00006676-199003000-00005. View

16.

Lemoine N, Hughes C, Barton C, Poulsom R, Jeffery R, Kloppel G . The epidermal growth factor receptor in human pancreatic cancer. J Pathol. 1992; 166(1):7-12. DOI: 10.1002/path.1711660103. View

17.

Rosenberg L, Barkun A, Denis M, Pollak M . Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer. 1995; 75(1):23-8. DOI: 10.1002/1097-0142(19950101)75:1<23::aid-cncr2820750106>3.0.co;2-a. View

18.

Mejia M, Navarro S, Pellin A, Castel V, Llombart-Bosch A . Study of bcl-2 protein expression and the apoptosis phenomenon in neuroblastoma. Anticancer Res. 1998; 18(2A):801-6. View

19.

Bell K, Bronner M, Pasha T, Furth E . Expression of proliferating cell nuclear antigen in gastrointestinal tract lesions and its relationship to bcl-2 expression. Pathobiology. 1996; 64(2):91-8. DOI: 10.1159/000164014. View

20.

Teixeira C, Reed J, PRATT M . Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res. 1995; 55(17):3902-7. View